Form 4: Lyell CSO Sells Shares for Tax Obligations

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold 138 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma, Inc. (LYEL), reported a transaction on November 10, 2025.
• The transaction involved the sale of 138 shares of Lyell Immunopharma Common Stock.
• The shares were sold at a price of $16.16 per share.
• The sale was executed to cover tax withholding obligations arising from the settlement of vested restricted stock units.
• Following this transaction, Gary K. Lee beneficially owns 15,366 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes, not indicative of positive or negative views on the company's future performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction, specifically a sale to cover tax obligations, which is common for executives receiving equity compensation. It does not reflect a discretionary sale based on market outlook or company performance, nor does it indicate any broader industry trends.

Stakeholder Impact

• Shareholders: Minimal impact as this is a small, routine, non-discretionary sale for tax purposes by an insider, not signaling a change in confidence or strategy.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of a small number of shares by the Chief Scientific Officer to cover tax obligations related to vested restricted stock units. Such transactions are common and do not typically reflect a change in the insider's outlook on the company's prospects or fundamental value. Therefore, this specific filing provides no new information that would warrant a change in investment recommendation; a 'hold' stance remains appropriate based solely on this report.

Keywords

Lyell Immunopharma, LYEL, Form 4, insider transaction, stock sale, tax withholding, restricted stock units, Gary K. Lee, Chief Scientific Officer